High-risk childhood acute lymphoblastic leukemia in China: Factors influencing the treatment and outcome

Pediatric Blood and Cancer

Volumn 52, Issue 2, 2009, Pages 191-195

  Luo, Xue Qun ^a   Ke, Zhi Yong ^a   Huang, Li Bin ^a   Guan, Xiao Qing ^a   Zhang, Ying Chuan ^a   Zhang, Xiao Li ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acute; Childhood; Developing countries; High risk; Leukemia; Lymphocytic

Indexed keywords

BCR ABL PROTEIN; METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHILD; CHINA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; INFANT; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TESTIS FUNCTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; DEVELOPING COUNTRY; MORTALITY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHINA; DEVELOPING COUNTRIES; FEMALE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 59449097126     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21810     Document Type: Article

References (14)

1. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904.
2. Tzortzatou-Stathopoulou F, Moshovi MA, Papadopoulou AL, et al. Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors? Eur J Haematol 2005;75:361-369.
3. Saarine-Pihkala UM, Gustafsson G, Carlsen N, et al. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regiment with restricted central nervous system irradiation. Pediatr Blood Cancer 2004;42:8-23.
4. Li CK, Chik KW, Chan GCF, et al. Treatment of lymphobkastic leukemia in Hong Kong children: HKALL 93 study. Hematol Oncol 2003;21:1-9.
5. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85 89 and 92. Leukemia 2000;14:2234-2239.
6. Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 2002;100:420-426.
7. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-4489.
8. Uderzo C, Balduzzi A. Allogeneic bone marrow transplantation versus chemotherapy in childhood very high risk acute lymphoblastic leukemia in first complete remission: A controversial issue. Haematologica 2002;87:47-50.
9. Smith M, Arthur D, Camtta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
10. Luo XQ, Ke ZY, Guan XQ, et al. The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China. Pediatr Blood Cancer 2008;51:204-209.
11. Bonilla M, Moreno N, Marina N, et al. Acute lymphoblastic leukemia in a developing country: Preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol 2000;22:495-501.
12. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukemia in first remision: Comparison by genetic randomization in an international prospective study. Lancet 2005;366:635-642.
13. Michael Boo JD. Public cord blood banking may play an important role in the emergence of unrelated transplant in developing countries. Transfusion 2007;48:207-208.
14. Yanada M, Takeuchi J, Sugiura I, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008;93:287-290.